CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

Inclusion Criteria:

* Newly diagnosed, histologically confirmed the following pathology subtype according to WHO 2008 classification: peripheral T Cell Lymphoma, not otherwise specified, angioimmunoblastic T cell lymphoma, ALK-negative anaplastic large cell lymphoma, enteropathy associated T cell lymphoma, subcutaneous panniculitis like T cell lymphoma, and hepatosplenic T-cell lymphoma.
* ≥ 16 years of age.
* Performance status of 2 or less.
* Has no history of malignancy.
* Has radiologically measurable disease.
* Life expectancy ≥6 months.
* Voluntarily sign an informed consent.

Exclusion Criteria:

* Pathology subtype with NK/T cell lymphoma, ALK positive-ALCL.
* Primary central nervous system (CNS) lymphoma.
* Previous systemic chemotherapy or local therapy.
* Has undergone hematopoietic stem-cell transplantation (HSCT).
* Has active infectious disease requiring general antibiotics, anti-fungal or anti-virus therapy.
* Has uncontrollable cardiocerebrovascular, coagulative, autoimmune, or serious infectious disease.
* Echocardiography shows left ventricular ejection fraction (LVEF) ≤ 50%.
* Inadequate renal, hepatic or bone marrow function
* Active liver or biliary disease.
* Has other uncontrollable medical condition that may interfere with their participation in the study.
* Woman in pregnancy or lactation.
* Patient is known to be positive for Human immunodeficiency virus (HIV) infection.